Deciphera Pharmaceuticals, Inc. develops small molecule kinase inhibitors for cancer, utilizing its proprietary kinase switch control inhibitor platform.
Revenue (Most Recent Fiscal Year) | $163.36M |
Net Income (Most Recent Fiscal Year) | $-194.94M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | 7.23 |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.34 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -119.07% |
Net Margin (Trailing 12 Months) | -119.33% |
Return on Equity (Trailing 12 Months) | -49.44% |
Return on Assets (Trailing 12 Months) | -38.41% |
Current Ratio (Most Recent Fiscal Quarter) | 3.80 |
Quick Ratio (Most Recent Fiscal Quarter) | 3.59 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
Inventory Turnover (Trailing 12 Months) | 0.15 |
Book Value per Share (Most Recent Fiscal Quarter) | $4.38 |
Earnings per Share (Most Recent Fiscal Quarter) | $-0.54 |
Earnings per Share (Most Recent Fiscal Year) | $-2.29 |
Diluted Earnings per Share (Trailing 12 Months) | $-2.29 |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
Common Shares Outstanding | 80.80M |
Free Float | 77.22M |
Market Capitalization | $1.18B |
Average Volume (Last 20 Days) | 0.46M |
Beta (Past 60 Months) | 0.39 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 4.43% |
Percentage Held By Institutions (Latest 13F Reports) | 70.96% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |